• ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome • Preliminary data showed ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts with confirmed CSF penetration • Based on PK data the therapeutic dose is expected to be ≤10mg once daily • To rapidly evaluate the anti-inflammatory activity of ACI-19764 (effect on hsCRP), dosing of a cardiovascular risk cohort is now underway with initial results expected by year end • Full results from the Phase 1/1b trial are expected in H1 2027
AC Immune SA, a clinical-stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases, today announced positive interim results from a Phase 1 first-in-human clinical study evaluating ACI-19764, its wholly-owned, orally administered small molecule inhibitor of the NLRP3 inflammasome.